News
Early promise for new immunotherapy combo in brain cancer
A combination treatment consisting of an experimental cancer drug – ipatasertib – and Roche’s immunotherapy agent Tecentriq (atezolizumab) has demonstrated early promise in an aggressive type of brain cancer.